Background {#Sec1}
==========

The administration of analgesic-antipyretic (ANAP) medications to children has been discussed in the literature for decades. Surveys of Canadian and American pediatricians reflect the routine use of acetaminophen and non-steroidal anti-inflammatory drugs (NSAID) for childhood fever and discomfort \[[@CR1], [@CR2]\]. In the 1980s, the term "fever phobia" was used to describe the parental pressure facing pediatric practitioners to manage fever \[[@CR3]\]. Parental misconceptions often lead parents to the inappropriate management of fever in their children \[[@CR4]\] and parents report the use of antipyretics even when there was minimal or no fever \[[@CR5]\] as parents were frequently concerned with the need to maintain a "normal temperature" in their ill child \[[@CR6]\]. Nevertheless, additional studies are needed to support this as evidence-based practice \[[@CR7], [@CR8]\]. Acetaminophen and NSAID are used widely in children, but limited data exist regarding patterns of use in countries beyond the United States, United Kingdom, France, and Canada \[[@CR9]\].

Notably, acetaminophen has been shown to have effects on glucose homeostasis. High doses have been shown to induce hyperglycemia \[[@CR10]\], whereas low and chronic doses can lower blood glucose in animal models \[[@CR11]--[@CR13]\]. Possible effects on asthma risk have also been investigated \[[@CR14], [@CR15]\]. NSAIDs have also been shown to lower blood glucose \[[@CR16], [@CR17]\], but have additional anti-inflammatory properties that could have an impact on the process leading up to T1D \[[@CR18]\].

The Environmental Determinants of Diabetes in the Young (TEDDY) Study is an international, multi-center study designed to identify the environmental triggers of T1D in genetically at-risk children \[[@CR19]\]. The aim of the current study was to describe the use of ANAP in the TEDDY study, as well as differences in relation to country, birth order (first child versus a child with older siblings) and fever status. Specifically, we sought to examine if the use of ANAP: (1) is associated with risk for islet autoimmunity (IA), (2) differs between countries, (3) is given preferentially to first-born children.

Methods {#Sec2}
=======

The Environmental Determinants of Diabetes in the Young (TEDDY) is a prospective cohort study funded by the National Institutes of Health with the primary goal to identify environmental causes of type 1 diabetes (T1D). It includes six clinical research centers - three in the US: Colorado, Georgia/Florida, Washington and three in Europe: Finland, Germany, and Sweden. Detailed study design and methods have been previously published \[[@CR19], [@CR20]\]. Written informed consents were obtained for all study participants from a parent or primary caretaker for genetic screening and participation in prospective follow-up. The study was approved by local Institutional or Ethics Review Boards (Additional file [1](#MOESM1){ref-type="media"}), and is monitored by an External Advisory Board formed by the National Institutes of Health.

Data collection {#Sec3}
---------------

The dataset analyzed was the data received by the TEDDY Data Coordinating Center as of December 31, 2014. The total number of subjects enrolled was 8676. Analysis was restricted to confirmed HLA eligible subjects and subjects with medication information in the first 2 years of age. Out of the enrolled subjects, 134 were missing medication data and were excluded from the analysis. Information regarding first child status was missing for 919 subjects who were also excluded, leaving a total of 7623 subjects (Additional file [2](#MOESM2){ref-type="media"}).

Study visits were conducted every 3 months with the first visit occurring between 3 and 4.5 months of age. At each visit, interviewers recorded the name, reason, start date and duration of reported medications for the most recent visit interval. Parents were asked to document fever as either "Yes" or "No" for every illness entry in a "TEDDY Book." The "TEDDY Book" provided written guidance that "Yes" should only be marked for temperature equal to or greater than 38 °C or 101 °F. Approximately 18 months into the study, these choices were expanded to "Yes -- measured," "Yes -- not measured," and "No." The rationale for this change was to capture all uses of ANAP, even with low-grade fevers.

Each use of an ANAP was defined as an episode. Recorded medications were categorized based on active ingredient. When analyzing specific substances, all medications containing that particular substance were included. Drugs were also defined and grouped as either analgesic or non-steroidal anti-inflammatory (NSAID) (Additional file [3](#MOESM3){ref-type="media"}). Episodes were described as associated with infection and/or fever. Infection was defined as either an ICD-10 code indicating Infection (Additional file [4](#MOESM4){ref-type="media"}) or an acute illness designated as infectious within a 15 day time period of the medication date \[[@CR21]\]. Fever was defined as either an ICD-10 code of fever associated with the medication or an acute illness associated with fever within a 15-day time period of the medication date.

Islet autoimmunity {#Sec4}
------------------

Blood samples were drawn every 3 months between 3 and 48 months of age, and every 6 months thereafter, except for autoantibody positive children, who continued with visits every 3 months. Persistent IA was defined as positive antibodies to insulin (IAA), glutamic acid decarboxylase (GAD65), or insulinoma-associated antigen 2 (IA-2), each analyzed by radiobinding assay \[[@CR22], [@CR23]\], on at least 2 consecutive study visits. Two central autoantibody laboratories were used; one in the U.S. (Barbara Davis Center for Childhood Diabetes at the University of Colorado) and one in Europe (University of Bristol). All positive islet autoantibodies and 5% of negative islet autoantibodies were confirmed in both central autoantibody laboratories. Both laboratories have previously demonstrated high sensitivity, specificity \[[@CR24]\] and concordance. Positive results in the child that were deemed to be due to maternal IgG transmission were excluded from the IA-positive group.

Statistical methods {#Sec5}
-------------------

A Cox proportional hazards model was used to assess the impact of ANAP use in the first 90, 180, 365 days of age and 2.5 years of age in the risk of positive autoantibodies through 6 years of age. The number of infections early in life was included as a time dependent covariate \[[@CR25]\]. Country was included as a stratification factor in the proportional hazards analyses. Additional covariates included in the model were first-degree relative \[[@CR26]\], HLA \[[@CR27]\], gender, ever breastfed \[[@CR28], [@CR29]\], probiotic use prior to 3 months of age \[[@CR30]\], and eight different previously identified single nucleotide polymorphisms \[[@CR31]\]. The primary variable of interest was cumulative ANAP use through 2.5 years of life as a time dependent covariate. Included covariates can be seen in Table [1](#Tab1){ref-type="table"}.Table 1Covariates included in the Cox proportionate hazards analysis of time to persistent confirmed autoantibody positivityFixed CovariatesHazard Ratio (95% CI)Wald test p-value^a^First-Degree Relative (Ref = No)2.51 (2.06, 3.30)\<0.001HLA (Ref = DR3/DR4)DR4/DR40.69 (0.54, 0.88)0.003DR4/DR80.70 (0.54, 0.91)0.008DR3/DR30.46 (0.35, 0.60)\<0.001All Others0.46 (0.29, 0.72)\<0.001Gender (Ref = male)0.77 (0.65, 0.92)0.003SNPRS1004446_a0.84 (0.74, 0.96)0.010RS10517086_a1.14 (1.00, 1.31)0.050RS12708716_g0.87 (0.76, 0.99)0.034RS2292239_a1.24 (1.09, 1.41)\<0.001RS2476601_a1.55 (1.31, 1.83)\<0.001RS2816316_c1.07 (0.91, 1.25)0.429RS3184504_a1.33 (1.17, 1.50)\<0.001RS4948088_a0.74 (0.53, 1.04)0.086Ever Breastfed (Ref = No)1.96 (1.01, 3.81)0.042Probiotics \<3 Mo Age (Ref = No)0.72 (0.55, 0.94)0.015Time Dependent CovariatesCumulative Number of Infections1.02 (0.99, 1.03)0.407Cumulative Weeks Analgesic Use1.02 (0.99, 1.04)0.269Number of persistent confirmed cases = 511^a^Ho: Hazard Ratio = 1

The statistical analysis for the number of episodes per year and duration per year excluded subjects for which the first child status was missing. Subjects with a missing duration for a specific analgesic were excluded from the analysis for that analgesic. The statistical analysis of total duration per year was based on log-transformed data to better satisfy the assumptions of the linear models.

Subject incidence was analyzed using logistic regression with country and first child status as independent variables in the model. In both the binary and continuous analyses, pairwise comparisons between countries were conducted using Holm's procedure to adjust for the multiplicity of comparisons. Each specific episode of ANAP usage was classified by concurrent fever (yes/no) or infection (yes/no). Episodes were categorized as associated with Fever, Infection, both Fever and Infection, or neither fever nor infection. For each categorization, a generalized estimating equation (GEE) was used for analysis with country and first child as independent variables in the model. An ignorable working matrix was assumed for the GEE analysis with the empirical sandwich estimate used for the standard errors. Pair-wise comparisons across countries were conducted using Holm's procedure from the GEE analyses. Analyses on the episode level excluded subjects who reported no episodes.

Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, U.S.A).

Results {#Sec6}
=======

Use of ANAP below the age of 2.5 years {#Sec7}
--------------------------------------

The use of both acetaminophen and NSAIDs were very common in the study population. In the total cohort, 87.8% of children reported the use of acetaminophen and 45.4% of NSAIDs before the age of 2.5 years. The mean number of treatment episodes per year was 3.6 ± 2.1 and mean duration of treatment 8.5 ± 10.8 days per year in the total cohort (Fig. [1a--c](#Fig1){ref-type="fig"}).Fig. 1Use of ANAP below 2,5 years of age. \*:*p* \< 0.05, n.s.: non significant. All significances corrected for multiple comparisons using Holm procedure. **a** Prevalence of analgesic/antipyretic use. **b** Treatment episodes per year. **c** Duration of medication use per year

Acetaminophen use {#Sec8}
-----------------

Swedish parents reported a significantly higher prevalence of acetaminophen use (94.5%), followed by U.S. (93.7%), Finnish (73.9%), and German parents (70.1%). Prevalence differed between all countries (Finland vs. Germany: *p* = 0.035, all other *p* \< 0.001). U.S. parents reported the highest number of treatment episodes per year and highest total duration of treatment per year (mean 4.0 ± 2.3 episodes; mean 9.8 ± 13.5 days), followed by Swedish (mean 3.6 ± 2.1 episodes; mean 8.4 ± 8.6 days), Finnish (mean 2.7 ± 1.9 episodes; mean 6.8 ± 6.4 days), and German parents (mean 2.5 ± 1.6 episodes; mean 4.7 ± 3.7 days). All country differences, according to number of treatment episodes, were statistically significant (Finland vs. Germany: *p* = 0.014, all others *p* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}). Children born as the first child in the family had more often been given acetaminophen during their first 2.5 years of life compared to children with older siblings (OR 1.26; 95% CI 1.07, 1.49; *p* = 0.007). The number of episodes of treatment with acetaminophen was also higher (difference in least square means 0.15; 95% CI 0.05, 9.24; *p* = 0.003). No difference could be seen regarding the number of days treated (difference in least square means 0.11; 95% CI -0.38, 0.60; *p* = 0.111).

NSAID use {#Sec9}
---------

The highest prevalence of NSAID use was reported by U.S. parents (58.3%), followed by German (44.1%), Finnish (42.3%), and Swedish parents (29.0%). All country differences, except between Finland and Germany, were statistically significant (Finland vs. Germany: *p* = 0.177, all others *p* \< 0.001). U.S. parents reported the highest number of treatment episodes with NSAID per year (mean 2.1 ± 1.4 episodes; mean 6.8 ± 11.2 days), followed by Swedish, Finnish, and German parents (mean 1.6 ± 1.2; mean 1.6 ± 1.2; mean 1.6 ± 1.1) Total duration of treatment was highest in the U.S. (mean 6.8 ± 11.2 days), followed by Finland (mean 5.3 ± 9.3 days), Germany (mean 5.2 ± 17.2 days), and Sweden (mean 4.9 ± 4.8 days). Both the mean number of treatment episodes and mean total duration of treatment were significantly higher in the U.S. compared to the other countries (*p* \< 0.001). No other significant country differences could be seen (Fig. [1](#Fig1){ref-type="fig"}). The prevalence of NSAID use during the first 2.5 years of life were lower in first-born children (OR 0.86; 95% CI 0.78, 0.95; *p* = 0.002) and they were also treated fewer times (difference in least square means −0.14; 95% CI -0.22, −0.05; *p* = 0.001). No differences could be seen regarding the number of days treated (difference in least square means −0.22; 95% CI -0.92, 0.48; *p* = 0.143).

Differences in use for febrile/infectious episodes and noninfectious use {#Sec10}
------------------------------------------------------------------------

In the total cohort, 74.1% of acetaminophen use and 82.0% of NSAID use was given in conjunction with either fever, infection or both, with 43.8% acetaminophen use and 51.0% NSAID episodes being combined fever and infection. U.S. parents reported a significantly higher proportion of doses given without fever or infection for both acetaminophen (40.4%) and NSAID (26.3%) compared to the other three countries (*p* \< 0.001). Acetaminophen use in feverish infectious episodes had the highest proportion among German and Swedish children (68.5% and 63.2%;), followed by Finland with 57.9% and the U.S. with 23.5% (all *p*-values for differences between countries were *p* \< 0.001, except between Germany and Swedenwas *p* = 0.003).

For NSAID use without fever or infection, the U.S. parents reported the highest proportion (26.3%), followed by Finland (7.7%), Germany (5.9%), and Sweden (3.7%) (difference between Finland and Sweden *p* = 0.006; between Germany and Sweden *p* = 0.01; all others *p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}).Fig. 2Fraction of treatment without fever and infection. \*:*p* \< 0.05, n.s.: non-significant. All significances corrected for multiple comparisons using Holm procedure Table 2Summary of treatment episodes associated with fever and/or infectionUSFinlandGermanySwedenTotal CohortCountry differencesU-FU-GU-SF-GF-SG-STotal episodesn25,3407427209117,28552,643AcetaminophenFever and infectionn42722907983922417,386\<0.001\<0.001\<0.001\<0.001\<0.0010.003Fever or infection65571277311342112,066No fever and no infectionn7348841141195310,283\<0.001\<0.001\<0.001\<0.0010.0060.01NSAIDFever and infectionn2680127347715726002\<0.001\<0.001\<0.001\<0.001\<0.0010.024Fever or infectionn24727171253303644No fever and no infectionn184116738742120\<0.001\<0.001\<0.0010.174\<0.0010.041Country differences: U = US, G = Germany, F = Finland, S = Sweden, Country differences described as *p*-value for difference between the respective countries

Islet autoimmunity {#Sec11}
------------------

Hazard ratios for islet autoimmunity were estimated for cumulative use of acetaminophen and NSAID with or without concomitant fever and for a joint variable of cumulative total ANAP use with or without fever. A significant hazard was only found for use of acetaminophen in the presence of fever for islet autoimmunity at age 3 years (HR 1.05; 95% CI 1.01-1.09; *p* = 0.024). The hazard was not significant for islet autoimmunity at 6 years of age (*p* = 0.193).

Separate analysis of exposure before 90, 180 and 365 days of life found a significant hazard for seroconversion at age 3 years (HR 1.06; 95% CI 1.00-1.12; *p* = 0.011) for use of acetaminophen with concurrent fever before 1 year of age, but not before 90 or 180 days of life (*p* = 0.91 and *p* = 0.54, respectively). No other significant hazards could be seen for treatment with acetaminophen or NSAID in the presence or absence of fever (Table [3](#Tab3){ref-type="table"}).Table 3Hazard ratios for seroconversion to persistent islet autoimmunity at 3 and 6 years of age for analgesic variables of interestAnalgesic VariableExposed subjects n (%)3 Year Analysis6 Year Analysis398 antibody + subjects511 antibody + subjectsHR (95% CI) *p*-valueHR (95% CI) *p*-valueAcetaminophen, any exposure7496 (87.8%)1.01 (0.97, 1.05) 0.6031.01 (0.98, 1.05) 0.576Acetaminophen with fever + infection5179 (60.6%)1.05 (1.01, 1.09) 0.0221.03 (0.99, 1.08) 0.189 Exposed \<90 days of life220 (2.6%)0.97 (0.59, 1.61) 0.9141.00 (0.68, 1.46) 0.986 Exposed \<180 days of life1519 (17.8%)1.07 (0.87, 1.32) 0.5421.06 (0.88, 1.27) 0.527 Exposed \<365 days of life3795 (44.4%)1.06 (1.00, 1.12) 0.0111.05 (0.99, 1.11) 0.101Acetaminophen without fever or infection5941 (69.6%)1.02 (0.98, 1.06) 0.3461.01 (0.96, 1.05) 0.769 Exposed \<90 days of life4016 (47.0%)1.00 (0.90, 1.11) 0.9940.99 (0.85, 1.14) 0.837 Exposed \<180 days of life4597 (53.8%)0.98 (0.84, 1.14) 0.8140.97 (0.84, 1.13) 0.729 Exposed \<365 days of life5310 (62.2%)1.03 (0.99, 1.06) 0.1141.02 (0.99, 1.06) 0.228NSAID, any exposure3874 (45.4%)1.01 (0.97, 1.05) 0.7531.01 (0.97, 1.04) 0.763NSAID with fever + infection2652 (31.0%)1.01 (0.97, 1.05) 0.6731.01 (0.98, 1.05) 0.459 Exposed \<90 days of life22 (0.3%)1.01 (0.92, 1.10) 0.8971.00 (0.92, 1.09) 0.960 Exposed \<180 days of life223 (2.6%)0.99 (0.88, 1.11) 0.8221.00 (0.94, 1.07) 0.927 Exposed \<365 days of life1318 (15.4%)1.01 (0.97, 1.06) 0.5301.02 (0.98, 1.05) 0.378NSAID without fever or infection1955 (22.9%)1.00 (0.96, 1.05) 0.8561.01 (0.97, 1.05) 0.623 Exposed \<90 days of life222 (2.6%)1.00 (0.88, 1.12) 0.9430.99 (0.88, 1.12) 0.874 Exposed \<180 days of life458 (5.4%)0.99 (0.88, 1.11) 0.8151.00 (0.94, 1.07) 0.956 Exposed \<365 days of life1120 (13.1%)1.01 (0.96, 1.06) 0.8241.01 (0.97, 1.05) 0.638Any analgesic, any exposure7744 (91%)1.02 (0.99, 1.05) 0.1301.02 (0.99, 1.04) 0.267Any analgesic with fever + infection5699 (67%)1.06 (0.97, 1.15) 0.2191.02 (0.94, 1.10) 0.667Each hazard ratio is calculated from a Cox proportional hazards model with the analgesic variable and covariates indicated in text

Discussion {#Sec12}
==========

In this study, we investigated the use of ANAP in children below the age of 2.5 years, and the impact of such use on the development of islet autoimmunity before 6 years of age in the large, longitudinal, international TEDDY cohort.

The widespread use of acetaminophen among young children has been of interest due not only to possible side effects, but also possible immunological effects. Several papers have investigated the impact on immune response and the development of autoimmunity \[[@CR11], [@CR12], [@CR32], [@CR33]\]. The data on childhood asthma is conflicting, with some studies showing an increased risk and others showing none \[[@CR14], [@CR15], [@CR34]\]. The use of prophylactic acetaminophen in conjunction with childhood vaccinations has also shown possible effects on antibody responses \[[@CR1], [@CR7], [@CR35]\]. In this study, we found a significant but weak increased hazard ratio associated with the use of acetaminophen and concomitant fever before the age of 2.5 years and persistent confirmed islet autoimmunity at age 3 years. However, this effect was not seen with islet autoimmunity at age 6 years or if acetaminophen was used for other reasons. It is therefore unlikely, although possible, that this is a true effect. The type of infection causing the fever may be a confounding factor. No such effect was seen with the use of NSAIDs or the combination of acetaminophen and NSAIDs, either when given with or without fever.

The use of acetaminophen and NSAIDs for the treatment of children has been previously described from a medical standpoint \[[@CR36], [@CR37]\]. On the other hand, very little has been described regarding practical use in the pediatric population. This analysis within a large international cohort provides some of the first data regarding pediatric use of ANAP. As expected,the majority of treatment episodes for this young cohort were in conjunction with fever and/or infection. It is worth mentioning that there are significant differences between the TEDDY countries regarding the use of both acetaminophen and NSAIDs. The U.S. stands out for both greater prevalence of use and greater number of episodes of treatment per year, followed closely by Sweden in regards to acetaminophen use. U.S. parents were also just as likely to report using these medications during episodes associated with infection than non-infectious episodes. Additionally, they were more likely to use ANAP when there was no associated fever. It may be a common practice of American physicians to prescribe a combination therapy approach to the use of analgesics and antipyretics forthe sustained management of fever. However, parents may then assume that even prophylactic use should be a combination therapy.

We also found that first-born children were preferentially given acetaminophen, both in prevalence of use and in the higher number of treatment episodes than for their younger siblings. The inverse relationship was observed for NSAID use, in which both the prevalence and number of treatment episodes were lower for first-born children. We can only speculate on the possible rationale behind this finding since, to our knowledge, no earlier study has presented similar data. It is possible that acetaminophen is perceived by first-time parents as a better tolerated treatmentthan NSAIDS, a perception that fades by the time younger siblings require treatment.

Country-specific differences in the use of analgesics may be culturally influenced. The lower incidence of use of all standard analgesics in Germany could reflect the prevalence of Complimentary Alternative Medicine (CAM) in this country. According to a cross-sectional survey of German physicians in 2007, more than two-thirds of patients in Germany use CAM provided either by physicians or non-medical practitioners ("Heilpraktiker") \[[@CR38]\]. In 2007, only 40% of adults in the U.S. had used CAM therapy in the past 12 months. Children in the U.S. whose parents used CAM were almost five times as likely (23.9%) to use CAM than children whose parent did not use CAM (5.1%) \[[@CR39]\]. The reasons underlying greater use of acetaminophen among Swedish parents is more unclear but may be the result of acetaminophen being widely available and perceived as safe and effective.

The TEDDY study is one of the largest longitudinal pediatric cohorts studied. The data analyzed herein has been collected from parent reports given in writing and after discussion with a TEDDY nurse. For participating children, missing data is uncommon. Follow-up is continuous from age 3 months which minimizes recall bias. The possibility to adjust for confounding factors in the statistical analysis is great due to the availability of comprehensive data on the child's living conditions. All previously described risk factors for T1D and islet autoimmunity are also entered into the statistical analysis of the effect of analgesics on islet autoimmunity.

The limitations of this study include our reliance on parent-reported symptoms and dosages of ANAP. The size of the cohort also makes it challenging to confirm diagnoses and treatment plans via patient records. Notably, most of the reported infections were presumed to be viral infections for which no medical advice had been sought. In addition, the widespread use of ANAP in this age group poses a significant statistical problem since the exposed group widely surpasses the non-exposed group. Even with the large sample size, the resulting correlation between IA and acetaminophen in combination with fever must therefore be interpreted with caution.

Conclusions {#Sec13}
===========

In conclusion, the use of ANAP to treat fever and infection is widespread in the TEDDY cohort but shows significant differences depending on study site. The prevalence of use of both acetaminophen and NSAIDs are highest in the U.S. and lowest in Finland and Germany. Use of both NSAIDs and acetaminophen for non-infectious purposes are significantly more common among children in the U.S. compared to those in Europe. No convincing effect on risk for autoimmunity can be seen in the analysis except for a small effect by acetaminophen in combination with fever, and then only for autoimmunity at 3 years of age.
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Additional file 1:Ethical review boards and Committees granting ethical approval to the TEDDY study. Listing of all ethical review boards and committes that has granted approval to the TEDDY study for the respective sites. (DOCX 59 kb) Additional file 2:Characteristics of the subjects used in analysis for analgesic use and islet cell autoimmunity. A table the prevalence of covariates in the present analysis including HLA-DQ genotype, Gender, first degree relative, breastfeeding, probiotic use and presence of included single nucleotide polymorphisms. (DOCX 106 kb) Additional file 3:List of Drugs defined as analgesics used in first 2.5 years in the TEDDY study. List of all included drugs, recorded to having been given to TEDDY children before age 2.5 years and classified as analgesics. Drugs classified as NSAID's are marked with a star (\*). (DOCX 30 kb) Additional file 4:List of all ICD-10 codes, recorded among TEDDY children before age 2.5 years, and classified as an infection. (DOCX 72 kb)
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